UNIGENE LABS INC (UGNE)

Overview Price 0.25 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank N/A - N/A Open Price $0.25 Previous Close $0.25 Daily Range $0.24 - $0.26 52-Week Range $0.18 - $1.28 Volume 8,724 Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. Other Resources for UGNE Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary No Commentary Found for This Ticker. Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics.   No brokerage coverage for UGNE   UGNE Ratings: BUY  SELL  HOLD UGNE Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 3 Buy 0 Sell   Top Buy Analysis No Buy Analysis. Be the First. More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

No related Blog Posts.

Commentary

BUY: UNIGENE LABS INC (UGNE) Start Price: $4.36 Points: -66.15 Created: 01/01/2008 Comments: 0 | Comment luckierod Recs:

BUY: UNIGENE LABS INC (UGNE) Start Price: $4.00 Points: -64.02 Created: 01/01/2008 Comments: 0 | Comment sophiedog Recs:

BUY: UNIGENE LABS INC (UGNE) Start Price: $2.79 Points: -52.85 Created: 01/01/2008 Comments: 0 | Comment woodleys Recs:

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
luckierod		BUY	Six Months to a Year	01/01/2008	$4.36	$1.03 (+14.44%)	-76.38%	-10.23%	-66.15
sophiedog	33.15	BUY	Six Months to a Year	01/01/2008	$4.00	$1.03 (+14.44%)	-74.25%	-10.23%	-64.02
woodleys		BUY	Six Months to a Year	01/01/2008	$2.79	$1.03 (+14.44%)	-63.08%	-10.23%	-52.85